CanSino Moving Coronavirus Vaccine To Phase III
CanSino plans to start a Phase III study soon for its candidate with a 40,000 enrollment target, discloses its co-founder.
You may also be interested in...
Coronavirus Update: GSK Signs Non-Coronavirus Deal With CureVac On mRNA Vaccines
Deal brings in new funding and commercial partner for CureVac, and gives GSK greater stake in fast-developing mRNA field.
Coronavirus Update: 'We Are Racing Against The Virus, Not America,' Says China’s Vaccine Frontrunner
Plus new biotech company Adagio Therapeutics has been launched with a $50m series A financing to advance its coronavirus antibodies as therapeutics and prophylactics.
Congressional Democrats Press US FDA For Transparency In Review Of COVID-19 Vaccines
FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.